Molecular Pharmacology

Cardiotonic steroids stabilize RGS2 protein levels

B. Sjögren, S. Parra, L. J. Heath, K. B. Atkins, Z-J. Xie, R. R. Neubig

Supplemental Table 1. Summary of hits from high-throutput screen of the Microsource Spectrum 2000 and the Biofocus NCC (NIH collection of FDA approved drugs) for compounds that increase RGS2 protein expression. The hits from the RGS2 screen can be divided into categories based on their previously known pharmacology. Note that digoxin was not a primary hit but was chosen for follow-up based on similarity to other CTS and that the majority of hits have not been confirmed in follow-up studies.

NAME	Viability (% of control)	RGS2 increase (% above control)	DRUG CLASS/USES
Gitoxin	103.1	81.9	
Sarmentogenin	95.1	59.4	Cardiotonic
Ouabain	90.1	51.1	steroids
Gitoxigenin	90.1	40.4	Storoids
Lanatoside C	92.3	26.5	
Vinblastine	90.6	83.3	
Mercaptopurine	98.2	59.7	Ch amath arany
5-Azacytidine; Vidaza	80.2	48.2	Chemotherapy
Retusoquinone	79.4	38.1	
Camptothecin	107.5	29.9	
Teniposide	97.2	26.8	
Mesna	93.3	22.8	
Crinamine	109.5	40.8	HIV-1
Nelfinavir Mesylate	87.3	28.5	Protease
Indinavir Sulphate	101.2	28.3	inhibitors
3-Hydroxyflavone	77.0	26.1	Flavonoids
Acacetin Diacetate	76.6	25.7	
Mundulone	95.6	25.1	
Deguelin	104.9	24.0	
Megestrol	89.5	29.3	Synthetic Steroid hormones
Ethinyl Estradiol	111.1	24.8	
Metaproterenol	95.2	24.7	
Fluticasone Propionate	93.7	21.4	Corticosteroids Asthma/Allergy
Flumethazone Pivalate	102.5	20.3	
Tacrolimus	98.7	30.4	Immunosuppressant
Thimerosal	68.3	47.2	Antiseptic agent
Monesin A	69.1	31.3	Antibiotic
Mexamine	89.2	24.8	Serotonin derivative
Nisoldipine	87.0	24.1	Hypertension; Ca2+ channel blocker
Dichlorophene	92.4	23.7	Antimicrobial agent
Hydroxychloroquine	92.6	22.5	Malaria
Flufenamic Acid	90.8	21.3	NSAID